Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Prolonged QT Interval in EKG and Sudden Death
Interventions
DRUG

Progesterone

Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days

DRUG

Placebo

Subjects will receive oral placebo two capsules once daily every evening for 7 days

DRUG

Ibutilide

Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval

Trial Locations (2)

46202

Indiana Clinical Research Center, Indianapolis

Purdue University, Indianapolis

All Listed Sponsors
collaborator

American Heart Association

OTHER

lead

Indiana University

OTHER

NCT01929083 - Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening | Biotech Hunter | Biotech Hunter